Shanghai Fosun Pharmaceutical (02196): Ibuprofen injection solution approved for registration

Shanghai Fosun Pharmaceutical (02196) announced that its controlling subsidiary Chongqing Yaoyou Pharmaceutical Co., Ltd. has obtained approval from the National Medical Products Administration for the drug registration application of Ibuprofen Ester Injection. The approved indication for this drug is postoperative and cancer pain relief. This drug is a chemical drug independently developed by the group. As of March 2026, the group's cumulative research and development investment for this drug is approximately RMB 34 million (unaudited). According to the latest data from IQVIA CHPA, the sales of Ibuprofen Ester Injection in China (excluding the Hong Kong, Macao, and Taiwan regions) in 2025 were approximately RMB 1.158 billion.